Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

  • Cancer
  • Colorectal Cancer (CRC)
  • Lung Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • Pancreatic Cancer
  • Pancreatic Adenocarcinoma
  • Tumor
  • Neoplasms
  • Ovarian Neoplasms
  • Renal Cell Cancer (RCC)
  • Renal Cell Carcinoma
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Terminated

This study runs in
Country
  • United States
Study Identifier:

NCT05769959 BP44068

      Show study locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Study Summary

      The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT05769959, BP44068 Study Identifier
      RO7515629, tocilizumab Treatments
      Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Ovarian Neoplasms Condition
      Official Title

      An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7515629 in Participants With Unresectable and/or Metastatic HLA-G Positive Solid Tumors

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Unresectable and/or metastatic HLA-G-positive solid tumors, for which standard therapy does not exist, or has proven to be ineffective or intolerable
      • Confirmed HLA-G tumor expression.
      • Radiologically measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
      • Life expectancy of at least 12 weeks
      • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
      • Adequate hematological, liver, renal and pulmonary function
      • Willingness to abide by protocol defined contraceptive requirements for the duration of the study.
      Exclusion Criteria
      • History or clinical evidence of Central Nervous System (CNS) metastases unless protocol specified criteria are met
      • Leptomeningeal metastases
      • Rapid disease progression including lesions that are a threat to vital organs or non-irradiated lesions 2cm or larger at critical sites where tumor swelling may pose a risk to critical anatomical structures
      • Participants with another invasive malignancy in the last 2 years unless protocol specified criteria are met
      • Uncontrolled hypertension
      • Active interstitial lung disease (ILD), pneumonitis or a history of ILD/pneumonitis requiring treatment with steroids, history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan
      • Participants with central cavitation or tumor(s) shown to be invading or abutting major blood vessels by imaging or the Investigator determines the tumor(s) is likely to invade major blood vessels and cause fatal bleeding
      • Participants with pulmonary military metastatic pattern or pulmonary lymphangitic carcinomatosis
      • History of pulmonary embolism within 3 months prior to study entry
      • Significant cardiovascular disease
      • Presence of active or uncontrolled infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to initiation of study treatment.
      • Known hepatitis B or C (actively replicating) based on protocol specified criteria
      • Known Human Immunodeficiency Virus (HIV) positivity
      • Presence of an indwelling line or drain
      • Active auto-immune disease that has required systemic therapy within the past 2 years unless protocol specified exceptions are met
      • Major surgery within 28 days prior to first study treatment
      • Last treatment with anti-cancer therapy or any investigational drug 28 days or less prior to the first study treatment
      • Last dose of immunostimulating or immunosuppressive therapy 28 days or less prior to the first study treatment
      • Regular dose of corticosteroids that exceeds prednisone 10 mg/day or equivalent within 28 days prior to first study treatment
      • Prior treatment with T cell engaging or adoptive cell therapy
      • Administration of a live, attenuated vaccine 28 days or less prior to first study treatment
      • Contraindication or known hypersensitivity to any of the components of RO7515629 or tocilizumab or dexamethasone

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Studies

      Use our search to find other studies on ForPatients in related disease areas.

      Colorectal Cancer (CRC) Non-Small Cell Lung Cancer (NSCLC) Pancreatic Adenocarcinoma Ovarian Neoplasms Renal Cell Carcinoma

      Clinical Research Explained

      Information about what clinical studies and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now